May 9, 2013

OUTPERFORM

Reason for report:

EARNINGS

Joseph P. Schwartz
(617) 918-4575
Joseph.Schwartz@Leerink.com

Michael Schmidt, Ph.D.
(617) 918-4588
Michael.Schmidt@Leerink.com

Paul Matteis
(617) 918-4585
Paul.Matteis@Leerink.com

LEERINK SWANN

HEALTHCARE EQUITY RESEARCH

HYPERION THERAPEUTICS, INC.

1Q13 EPS - Ravicti Launch Underway, Bullish on Quick Patient Uptake

• **Bottom Line**: Today after the close HPTX reported 1Q13 EPS of ($0.52) versus our estimate of ($0.80) and was able to recognize the first Ravicti (urea cycle disorders [UCD]) revenues after launching Ravicti one month earlier than we and the Street anticipated. We believe HPTX's ahead-of-schedule Ravicti launch reflects the company's extensive commercial preparedness and its ability to execute with a lean and effective organization. We have updated our model to reflect 1Q13 results, HPTX's follow-on equity offering, and have increased our Ravicti sales projections in 2013 and 2014. With roughly half of the clinical trial patients transitioned to commercial Ravicti, our 2013 HPTX revenue estimate of $29MM may even be conservative. **Reiterate Outperform on HPTX, increasing our 12 month FVE to $33 from $30 previously.**

• **Management is encouraged by the physician demand they've seen for Ravicti, with more than half of the prescribers coming from outside the Ravicti clinical trial.** While HPTX did not provide specific patient or TRx guidance, the company is very impressed with physician interest in Ravicti with ~25% of targeted prescribers writing at least one TRx thus far. We believe the recent emergence of Sigma-Tau's generic Buphenyl will not have a significant influence on Ravicti. With only a 13% spread between branded and generic Buphenyl, which already costs just $76k/patient/year vs. $277k/patient/year for Ravicti, we do not believe that Buphenyl's lower price will be able to prevent patients from switching to Ravicti and should not inhibit HPTX from recognizing branded Buphenyl sales as planned.

• **We continue to believe that Ravicti is best-in-class for UCD, and Buphenyl presents a variety of issues to UCD patients.** These include but are not limited to a large dose burden, frequent (3-6 times/day) administration, unpleasant taste and smell, tolerability issues, and high sodium content. From a physician point-of-view, easier patient compliance to Ravicti therapy may enable better disease management ultimately translating into fewer hyperammonemic (HA) crises relative to what is currently available with Buphenyl. This should be attractive to payors, who in our checks do not indicate a willingness to manage this ultra-orphan category.

• **We anticipate that VRX will exercise its option to retain Ammunol, essentially providing Buphenyl to HPTX for free along with a ~ $13MM gain.** Recall, HPTX recently exercised its option to purchase all of Ucyclyd's (now VRX) WW rights in Buphenyl and Ammonul for an upfront payment of $22MM, but VRX now has until May 22 to retain Ammunol at a purchase price of $32MM.

Key Stats:	**(NASDAQ:HPTX)**
S&P 600 Health Care Index:	**946.00**
Price:	**$21.09**
52 Week High:	$26.50
52 Week Low:	$9.95
Shares Outstanding (mil):	16.6
Market Capitalization (mil):	$350.1
Book Value/Share:	$0.00
Cash Per Share:	$2.00
Dividend (ann):	$0.00
Dividend Yield:	0.0%
Valuation:	$33 from $30 on DCF



Dec Yr	1Q	2Q	3Q	4Q	FY Rev	1Q	2Q	3Q	4Q	FY EPS	P/E
2012A	0.0	0.0	0.0	0.0	0.0	($25.33)	($15.26)	($0.44)	($0.50)	($4.45)	NM
2013E - New	**$0.8A**	**$1.5**	**$9.6**	**$16.6**	**$28.5**	**($0.52)**	**$0.03**	**($0.52)**	**($0.24)**	**($1.24)**	**NM**
2013E - Old	0.0	0.0	$6.4	$9.3	$15.7	($0.80)	($0.04)	($0.53)	($0.44)	($1.81)	NM
2014E - New	**--**	**--**	**--**	**--**	**$100.4**	**--**	**--**	**--**	**--**	**$0.79**	**26.7x**
2014E - Old	--	--	--	--	$99.1	--	--	--	--	$1.17	NM

Source: Company Information and Leerink Swann LLC Research
Revenues in millions. Diluted EPS. HPTX completed an IPO on 7/31/12.

Please refer to pages 8 - 10 for Important Disclosures, Price Charts and Analyst Certification.

INVESTMENT THESIS

We believe that HPTX shares present an attractive opportunity to invest in the orphan drug business model and rate the stock Outperform. Lead agent Ravicti is in late-stage development for urea cycle disorders (UCD) and hepatic encephalopathy (HE), two rare diseases characterized by elevated levels of ammonia in the bloodstream, which can cause significant neurological complications. HPTX generated positive Phase III data for Ravicti in adult urea cycle disorder patients and obtained FDA approval pursuant to a special protocol assessment (SPA). HPTX has also completed Phase II trials for Ravicti in HE and had an end-of-Phase II meeting in 4Q:12. Ravicti has a similar mechanism of action to already FDA-approved Buphenyl, the use of which is constrained by a large dose burden, frequent (3-6 times/day) administration, unpleasant taste and smell, tolerability issues, and high sodium content. Easier patient compliance to Ravicti therapy may enable better disease management ultimately translating into fewer hyperammonemic (HA) crises relative to what is currently available with Buphenyl. The rate of HA crises with Ravicti was 40% lower than that seen for Buphenyl in the 12-month safety extension study following HPTX's pivotal Phase III trial. HPTX is led by seasoned orphan drug company executives who have stayed close to key physicians and patient support organizations who are expected to influence Ravicti uptake. HPTX launched Ravicti in March 2013, a month ahead of expectations, with a lean team of experienced personnel including seven field sales representatives, one senior director who manages the group, and also a payor specialist team of four. On the clinical side, HPTX has a medical science liaison team of four specialists, consisting of one director and three field-based specialists running back-office operations. We project that HPTX achieves breakeven in 2014 and generates peak sales around $150MM in UCD in 2030. HPTX may influence the conversion and expansion of the UCD market since the company has the option to purchase worldwide rights to Buphenyl and Ammonul from MRX for $22MM, which may be funded by drawing on a loan commitment from MRX. HE presents an upside market opportunity of around $500MM, in our estimation. In contrast to SLXP's (MP) Xifaxan, which blocks nitrogen absorption in the gut for HE patients, Ravicti lowers ammonia systemically by increasing its clearance. Ravicti could thus potentially be complementary to currently approved agents that limit the local production of ammonia. HPTX completed a Phase II clinical study of similar design to the pivotal trial used to evaluate Xifaxan, the only therapy approved by the FDA for episodic HE within the last 30 years. Phase II data indicate that Ravicti may have superior efficacy compared to Xifaxan and may improve outcomes when given in combination.

VALUATION

Our 12-month fair value estimate for HPTX is $33/share based on discounted cash flow (DCF) analysis. We assume a 12% discount rate and 5% terminal growth rate. We discount free cash flow until 2030E, when orphan drug exclusivity for Ravicti for treating UCD expires.

RISKS TO VALUATION

The key risks to HPTX's valuation include the potential for disappointing clinical data, regulatory setbacks, and commercial and financial shortfalls. Since HPTX presently has only one late-stage product candidate, any of those possible setbacks may impact the stock significantly.

HPTX P&L ($MM)	2010	2011	1Q12	2Q12	3Q12	4Q12	2012	1Q13	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E
Revenue	-	-	-	-	-	-	-	0.8	1.5	9.6	16.6	28.5	100.4	115.7
COGS	-	-	-	-	-	-	-	0.1	0.2	1.4	2.5	4.2	15.1	17.4
R&D	23.1	17.2	8.9	2.7	2.4	3.0	17.0	1.8	5.0	8.0	8.0	22.8	30.1	34.7
SG&A	3.5	8.9	2.3	2.0	2.4	4.8	11.5	7.9	8.5	9.0	10.0	35.4	39.0	40.9
Operating expenses	26.6	26.2	11.2	4.8	4.8	7.8	28.5	9.9	13.7	18.4	20.5	62.5	84.2	93.0
Operating income	(26.6)	(26.2)	(11.2)	(4.8)	(4.8)	(7.8)	(28.5)	(9.1)	(12.2)	(8.8)	(3.9)	(34.0)	16.2	22.7
Total other income (expense)	1.1	(3.3)	(0.7)	(2.4)	(0.2)	(0.5)	(3.7)	0.1	12.8	(0.2)	(0.2)	12.4	(0.8)	(0.1)
EBT	(25.5)	(29.4)	(11.9)	(7.2)	(4.9)	(8.3)	(32.3)	(9.0)	0.5	(9.0)	(4.1)	(21.6)	15.5	22.6
Tax expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)	(25.5)	(29.4)	(11.9)	(7.2)	(4.9)	(8.3)	(32.3)	(9.0)	0.5	(9.0)	(4.1)	(21.6)	15.5	22.6
Diluted EPS	**(61.70)**	**(62.68)**	**(25.33)**	**(15.26)**	**(0.44)**	**(0.50)**	**(4.45)**	**(0.52)**	**0.03**	**(0.52)**	**(0.24)**	**(1.24)**	**0.79**	**1.15**
Basic shares outstanding	0.4	0.5	0.5	0.5	11.3	16.6	7.3	17.4	17.4	17.4	17.4	17.4	17.5	17.6

Source: SEC filings and Leerink Swann Estimates

HPTX BS	2010	2011	1Q12	2Q12	3Q12	4Q12	2012	1Q13	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E
Cash	**6.6**	**7.0**	**3.7**	**7.3**	**56.5**	**49.9**	**49.9**	**102.7**	**104.3**	**96.6**	**94.0**	**94.0**	**116.3**	**134.5**
Debt	**-**	**23.4**	**30.7**	**40.5**	**12.0**	**12.1**	**12.1**	**12.0**	**12.0**	**12.0**	**12.0**	**12.0**	**12.0**	**-**
Convertible notes	-	23.4	30.7	31.2	-	-	-	-	-	-	-	-	-	-
Venture debt	-	-	-	9.4	12.0	12.1	12.1	12.0	12.0	12.0	12.0	12.0	12.0	-
Ucyclyd loan	-	-	-	-	-	-	-	-	-	-	-	-	-	-

HPTX CFS	2010	2011	1Q12	2Q12	3Q12	4Q12	2012	1Q13	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E
Change in cash	**(3.5)**	**0.4**	**(3.3)**	**3.6**	**49.2**	**(6.7)**	**42.8**	**52.8**	**1.6**	**(7.7)**	**(2.6)**	**44.1**	**22.4**	**18.1**
Cash from operations	**(25.9)**	**(24.5)**	**(10.7)**	**(5.8)**	**(5.7)**	**(6.3)**	**(28.5)**	**(10.8)**	**1.6**	**(7.7)**	**(2.6)**	**(19.5)**	**22.4**	**30.1**
Net Income	(25.5)	(29.4)	(11.9)	(7.2)	(4.9)	(8.3)	(32.3)	(9.0)	0.5	(9.0)	(4.1)	(21.6)	15.5	22.6
SOE	0.2	0.3	0.1	0.2	0.3	0.4	1.0	0.5	1.1	1.4	1.4	4.4	6.9	7.6
Other	(0.6)	4.5	1.1	1.1	(1.1)	1.6	2.7	(2.3)	-	-	-	(2.3)	-	-
Cash from investing	**(0.0)**	**(0.0)**	**(0.1)**	**0.2**	**(0.0)**	**(0.0)**	**0.0**	**(0.1)**	**-**	**-**	**-**	**(0.1)**	**-**	**-**
Option to purchase Buphenyl	-	-	(0.3)	-	-	-	(0.3)	-	-	-	-	-	-	-
Other	(0.0)	(0.0)	0.2	0.2	(0.0)	(0.0)	0.3	(0.1)	-	-	-	(0.1)	-	-
Cash from financing	**22.4**	**25.0**	**7.6**	**9.2**	**55.0**	**(0.4)**	**71.4**	**63.7**	**-**	**-**	**-**	**63.7**	**-**	**(12.0)**
Issuance (buyback) shares	22.5	-	(0.0)	0.1	53.4	-	53.5	63.7	-	-	-	63.7	-	-
Issuance (repay) debt	-	25.0	7.5	10.0	2.5	-	20.0	-	-	-	-	-	-	(12.0)
Other	(0.0)	-	0.1	(0.9)	(0.9)	(0.4)	(2.1)	-	-	-	-	-	-	-

Source: SEC filings and Leerink Swann Estimates

UCD Scenario 1: Ravicti approved in UCD only	2012E	1Q13E	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Total US pts diagnosed	1,000	1,002	1,004	1,006	1,009	1,005	1,014	1,022	1,031	1,040	1,049	1,058	1,067
Total untreated pts	575	576	577	579	580	578	583	588	593	598	603	608	613
patients < age 6	161	161	162	162	162	162	163	165	166	167	169	170	172
patients age 6-17	184	184	185	185	186	185	187	188	190	191	193	195	196
adults	230	230	231	231	232	231	233	235	237	239	241	243	245
Total Buphenyl treated pts	425	426	427	428	429	427	431	435	438	442	446	450	453
patients < age 6	119	119	120	120	120	120	121	122	123	124	125	126	127
patients age 6-17	136	136	137	137	137	137	138	139	140	141	143	144	145
adults	170	170	171	171	171	171	172	174	175	177	178	180	181
Untreated pts on Ravicti	-	-	-	6	46	13	64	88	119	120	121	122	123
penetration, patients < age 6	0%	0%	0%	1%	8%	2%	11%	15%	20%	20%	20%	20%	20%
penetration, patients age 6-17	0%	0%	0%	1%	8%	2%	11%	15%	20%	20%	20%	20%	20%
penetration, adults	0%	0%	0%	1%	8%	2%	11%	15%	20%	20%	20%	20%	20%
Prior Buphenyl treated pts on Ravicti	-	14	26	86	171	74	302	391	438	442	446	450	453
penetration, patients < age 6	0%	3%	6%	20%	40%	17%	70%	90%	100%	100%	100%	100%	100%
penetration, patients age 6-17	0%	3%	6%	20%	40%	17%	70%	90%	100%	100%	100%	100%	100%
penetration, adults	0%	3%	6%	20%	40%	17%	70%	90%	100%	100%	100%	100%	100%
Total Ravicti pts	-	14	26	91	218	87	366	479	557	562	566	571	576
Avg cost/pt($mm)	-	0.058	0.058	0.058	0.058	0.230	0.230	0.230	0.230	0.230	0.230	0.230	0.230
Ravicti US sales in UCD ($MM)	**-**	**0.8**	**1.5**	**5**	**13**	**20**	**84**	**110**	**128**	**129**	**130**	**131**	**132**

Buphenyl Model Private Payors	2012E	1Q13E	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Patients on Buphenyl	425	412	401	342	257	353	129	43	-	-	-	-	-
Branded Buphenyl market private payor	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*10%*	*0%*	*0%*	*0%*
Avg cost/pt	0.056	0.019	0.019	0.019	0.019	0.075	0.230	0.230	0.230	0.230	0.230	0.230	0.230
Buphenyl US sales in UCD ($MM)	**10**	**3**	**3**	**3**	**2**	**11**	**12**	**4**	**-**	**-**	**-**	**-**	**-**

Buphenyl Model Medicare/Medicaid	2012E	1Q13E	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Patients on Buphenyl	425	412	401	342	257	353	129	43	-	-	-	-	-
Branded Buphenyl market public payor	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*10%*	*0%*	*0%*	*0%*
Avg cost/pt	0.056	0.014	0.014	0.014	0.014	0.056	0.056	0.056	0.056	0.056	0.056	0.056	0.056
Buphenyl US sales in UCD ($MM)	**14**	**3**	**3**	**3**	**2**	**12**	**4**	**1**	**-**	**-**	**-**	**-**	**-**

Total Buphenyl US sales ($MM)	**24**			**5**	**4**	**23**	**16**	**5**	**-**	**-**	**-**	**-**	**-**

Total sales Ravicti + Buphenyl	**33**	**1**	**1**	**10**	**17**	**29**	**100**	**116**	**128**	**129**	**130**	**131**	**132**

Source: SEC filings and Leerink Swann Estimates

UCD Scenario 2: Ravicti approved in HE	2012E	1Q13E	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Total US UCD pts diagnosed	1,000	1,002	1,004	1,006	1,009	1,005	1,014	1,022	1,031	1,040	1,049	1,058	1,067
Total untreated pts	575	576	577	579	580	578	583	588	593	598	603	608	613
patients < age 6	161	161	162	162	162	162	163	165	166	167	169	170	172
patients age 6-17	184	184	185	185	186	185	187	188	190	191	193	195	196
adults	230	230	231	231	232	231	233	235	237	239	241	243	245
Total Buphenyl treated pts	425	426	427	428	429	427	431	435	438	442	446	450	453
patients < age 6	119	119	120	120	120	120	121	122	123	124	125	126	127
patients age 6-17	136	136	137	137	137	137	138	139	140	141	143	144	145
adults	170	170	171	171	171	171	172	174	175	177	178	180	181
Untreated pts on Ravicti	-	-	-	6	46	13	64	88	119	120	121	122	123
penetration, patients < age 6	0%	0%	0%	1%	8%	2%	11%	15%	20%	20%	20%	20%	20%
penetration, patients age 6-17	0%	0%	0%	1%	8%	2%	11%	15%	20%	20%	20%	20%	20%
penetration, adults	0%	0%	0%	1%	8%	2%	11%	15%	20%	20%	20%	20%	20%
Prior Buphenyl treated pts on Ravicti	-	14	26	86	171	74	302	391	438	442	446	450	453
penetration, patients < age 6	0%	3%	6%	20%	40%	17%	70%	90%	100%	100%	100%	100%	100%
penetration, patients age 6-17	0%	3%	6%	20%	40%	17%	70%	90%	100%	100%	100%	100%	100%
penetration, adults	0%	3%	6%	20%	40%	17%	70%	90%	100%	100%	100%	100%	100%
Total Ravicti pts	-	14	26	91	218	87	366	479	557	562	566	571	576
Avg cost/pt($mm)	-	0.058	0.058	0.058	0.058	0.230	0.230	0.230	0.230	0.070	0.070	0.070	0.070
Ravicti US sales in UCD ($MM)	**-**	**1**	**1**	**5**	**13**	**20**	**84**	**110**	**128**	**39**	**40**	**40**	**40**

Buphenyl Model Private Payors	2012E	1Q13E	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Patients on Buphenyl	425	412	401	342	257	353	129	43	-	-	-	-	-
Branded Buphenyl market private payor	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*40%*	*10%*	*0%*	*0%*	*0%*
Avg cost/pt	0.056	0.019	0.019	0.019	0.019	0.075	0.230	0.230	0.230	0.070	0.070	0.070	0.070
Buphenyl US sales in UCD ($MM)	**10**	**3**	**3**	**3**	**2**	**11**	**12**	**4**	**-**	**-**	**-**	**-**	**-**

Buphenyl Model Medicare/Medicaid	2012E	1Q13E	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Patients on Buphenyl	425	412	401	342	257	353	129	43	-	-	-	-	-
Branded Buphenyl market public payor	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*60%*	*10%*	*0%*	*0%*	*0%*
Avg cost/pt	0.056	0.014	0.014	0.014	0.014	0.056	0.056	0.056	0.056	0.056	0.056	0.056	0.056
Buphenyl US sales in UCD ($MM)	**14**	**3**	**3**	**3**	**2**	**12**	**4**	**1**	**-**	**-**	**-**	**-**	**-**

Total Buphenyl US sales ($MM)	24	7	6	5	4	23	16	5	-	-	-	-	-

Ravicti for HE	2012E	1Q13E	2Q13E	3Q13E	4Q13E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Total US HE pts diagnosed	140,000	140,297	140,594	140,892	141,190	140,743	141,939	143,146	144,363	145,590	146,827	148,075	149,334
Total severe HE patients	28,000	28,059	28,119	28,178	28,238	28,149	28,388	28,629	28,873	29,118	29,365	29,615	29,867
% severe HE patients	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*	*20%*
% Ravicti patients	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*5%*	*10%*	*15%*	*25%*
Ravicti pts in HE	-	-	-	-	-	-	-	-	-	1,456	2,937	4,442	7,467
Avg cost/pt($mm)	-	-	-	-	-	-	-	-	-	0.070	0.070	0.070	0.070
Ravicti US sales in HE ($MM)	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**102**	**206**	**311**	**523**

Total sales Ravicti + Buphenyl	33	1	1	10	17	29	100	116	128	141	245	351	563

Source: SEC filings and Leerink Swann Estimates

HPTX DCF (Scenario 1)	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	TV
FCF	(19)	22	30	29	57	89	136	218	211	213	215	216	73	57	37	25	25	21	4	
Discount periods	-	0.8	1.8	2.8	3.8	4.8	5.8	6.8	7.8	8.8	9.8	10.8	11.8	12.8	13.8	14.8	15.8	16.8	17.8	
NPV	(19)	21	25	21	37	52	71	102	88	79	71	64	19	13	8	5	4	3	1	8
Valuation	671																			

Discount Rate	12%
Terminal Growth	5%

Valuation	Valuation	per shr	Probability	P/W
Scenario 1, Ravicti approved for UCD only	327	$ 17	35%	**114**
Scenario 2, Ravicti approved for UCD and HE	671	$ 35	65%	**436**
Blended Valuation				**551**
Net cash				82.0
Diluted Shares Outstanding				19.4
Per share valuation				**$ 33**

Source: SEC filings and Leerink Swann Estimates

Hyperion Therapeutics, Inc. (HPTX) Expected Milestones			Timing
Ammunol		Expiration MRX/VRX right to retain Ammunol	5/22/2013
Ravicti		2 addl. patent allowances	2013
Ravicti	HE	Phase III initiation	2014
Ravicti	HE	Phase III data	2015
Ravicti	HE	sNDA filing	2016
Ravicti	HE	sNDA approval	2017

Source: Company reports, Leerink Swann LLC estimates

LEERINK SWANN

Disclosures Appendix

Analyst Certification

I, Joseph P. Schwartz, certify that the views expressed in this report accurately reflect my views and that no part of my compensation was, is, or will be directly related to the specific recommendation or views contained in this report.

Valuation

Our 12-month fair value estimate for HPTX is $33/share based on discounted cash flow (DCF) analysis. We assume a 12% discount rate and 5% terminal growth rate. We discount free cash flow until 2030E, when orphan drug exclusivity for Ravicti for treating UCD expires.

Risks to Valuation

The key risks to HPTX's valuation include the potential for disappointing clinical data, regulatory setbacks, and commercial and financial shortfalls. Since HPTX presently has only one late-stage product candidate, any of those possible setbacks may impact the stock significantly.



Distribution of Ratings/Investment Banking Services (IB) as of 03/31/13			IB Serv./Past 12 Mos.	
Rating	Count	Percent	Count	Percent
BUY [OP]	107	61.14	32	29.91
HOLD [MP]	68	38.86	0	0.00
SELL [UP]	0	0.00	0	0.00

Explanation of Ratings

Outperform (Buy): We expect this stock to outperform its benchmark over the next 12 months.

Market Perform (Hold/Neutral): We expect this stock to perform in line with its benchmark over the next 12 months.

Underperform (Sell): We expect this stock to underperform its benchmark over the next 12 months.The degree of outperformance or underperformance required to warrant an Outperform or an Underperform rating should be commensurate with the risk profile of the company.

For the purposes of these definitions the relevant benchmark will be the S&P 600® Health Care Index for issuers with a market capitalization of less than $2 billion and the S&P 500® Health Care Index for issuers with a market capitalization over $2 billion.

From October 1, 2006 through January 8, 2009, the relevant benchmarks for the above definitions were the Russell 2000® Health Care Index for issuers with a market capitalization of less than $2 billion and the S&P 500® Health Care Index for issuers with a market capitalization over $2 billion.

Definitions of Leerink Swann Ratings prior to October 1, 2006 are shown below:

Outperform (Buy): We expect this stock to outperform its benchmark by more than 10 percentage points over the next 12 months.

Market Perform (Hold/Neutral): We expect this stock to perform within a range of plus or minus 10 percentage points of its benchmark over the next 12 months.

Underperform (Sell): We expect this stock to underperform its benchmark by more than 10 percentage points over the next 12 months.

For the purposes of these definitions, the relevant benchmark were the Russell 2000® Health Care Index for issuers with a market capitalization of less than $2 billion and the S&P 500® Index for issuers with a market capitalization over $2 billion.

Important Disclosures

This information (including, but not limited to, prices, quotes and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice. This is provided for information purposes only and should not be regarded as an offer to sell or as a solicitation of an offer to buy any product to which this information relates. The Firm, its officers, directors, employees, proprietary accounts and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this report. The Firm's salespeople, traders and other professionals may provide oral or written market commentary or trading strategies that are contrary to opinions expressed in this report. The Firm's asset management group and proprietary accounts may make investment decisions that are inconsistent with the opinions expressed in this report. The past performance of securities does not guarantee or predict future performance. Transaction strategies described herein may not be suitable for all investors. Additional information is available upon request by contacting the Publishing Department at One Federal Street, 37th Floor, Boston, MA 02110.

Like all Firm employees, analysts receive compensation that is impacted by, among other factors, overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Equities, and Investment Banking. Analysts, however, are not compensated for a specific investment banking services transaction.

Leerink Swann Consulting LLC, an affiliate of Leerink Swann LLC, is a provider of evidence-based strategy and consulting to the healthcare industry.

In the past 12 months, the Firm has received compensation for providing investment banking services to Hyperion Therapeutics, Inc.

Leerink Swann LLC makes a market in Hyperion Therapeutics, Inc.

Leerink Swann LLC has acted as the manager for a public offering of Hyperion Therapeutics, Inc. in the past 12 months.

Leerink Swann LLC Equity Research

Director of Equity Research	**John L. Sullivan, CFA**	(617) 918-4875	john.sullivan@leerink.com
Associate Director of Research	**Alice C. Avanian, CFA**	(617) 918-4544	alice.avanian@leerink.com
Healthcare Strategy	**John L. Sullivan, CFA**	(617) 918-4875	john.sullivan@leerink.com
	Alice C. Avanian, CFA	(617) 918-4544	alice.avanian@leerink.com
Biotechnology	**Howard Liang, Ph.D.**	(617) 918-4857	howard.liang@leerink.com
	Joseph P. Schwartz	(617) 918-4575	joseph.schwartz@leerink.com
	Marko Kozul, M.D.	(415) 905-7221	marko.kozul@leerink.com
	Michael Schmidt, Ph.D.	(617) 918-4588	michael.schmidt@leerink.com
	Irene Lau	(415) 905-7256	irene.lau@leerink.com
	Rene Shen	(212) 277-6074	rene.shen@leerink.com
	Gena Wang, Ph.D.	(212) 277-6073	gena.wang@leerink.com
	Paul Matteis	(617) 918-4585	paul.matteis@leerink.com
Life Science Tools and Diagnostics	**Dan Leonard**	(212) 277-6116	dan.leonard@leerink.com
	John L. Sullivan, CFA	(617) 918-4875	john.sullivan@leerink.com
	Justin Bowers, CFA	(212) 277-6066	justin.bowers@leerink.com
Pharmaceuticals/Major	**Seamus Fernandez**	(617) 918-4011	seamus.fernandez@leerink.com
	Swati Kumar	(617) 918-4576	swati.kumar@leerink.com
Specialty Pharmaceuticals, Generics	**Jason M. Gerberry, JD**	(617) 918-4549	jason.gerberry@leerink.com
	Christopher W. Kuehnle, JD	(617) 918-4851	chris.kuehnle@leerink.com
Medical Devices, Cardiology & Orthopedics	**Danielle Antalffy**	(212) 277-6044	danielle.antalffy@leerink.com
	Richard Newitter	(212) 277-6088	richard.newitter@leerink.com
	Robert Marcus, CFA	(212) 277-6084	robert.marcus@leerink.com
Healthcare Technology & Distribution	**David Larsen, CFA**	(617) 918-4502	david.larsen@leerink.com
	Christopher Abbott	(617) 918-4010	chris.abbott@leerink.com
Sr. Editor/Supervisory Analyst	**Mary Ellen Eagan, CFA**	(617) 918-4837	maryellen.eagan@leerink.com
Supervisory Analysts	Robert Egan		bob.egan@leerink.com
	Amy N. Sonne		amy.sonne@leerink.com
Research Assistant	Paul Matteis	(617) 918-4585	paul.matteis@leerink.com
	George Villarina	(212) 277-6012	george.villarina@leerink.com

New York
1251 Avenue of Americas, 22nd Floor
New York, NY 10020
(888) 347-2342

Boston
One Federal Street, 37th Floor
Boston, MA 02110
(800) 808-7525

San Francisco
201 Spear Street, 16th Floor
San Francisco, CA 94105
(800) 778-1164